initiation. The sub-cohort of patients switching to dronedarone from Prior Rhythm-Control therapy (n = 2,080) showed similar reductions in hospital and emergency department events.
trial demonstrated a significant reduction (26%) in the rate of first cardiovascular (CV) hospitalization in dronedarone-treated patients with paroxysmal or persistent atrial fibrillation/ flutter (AF/AFL). ATHENA was the first trial to demonstrate a CV outcomes benefit, specifically reduced CV hospitalizations, with an antiarrhythmic drug. The objective of this study was to assess the impact of dronedarone treatment on healthcare resource utilization among real-world patients with AF/AFL in United States clinical practice.
Methods: This retrospective cohort study used claims data from the MarketScan Ò databases (Truven Health, Durham, NC, USA) to identify patients with C2 concurrent de novo pharmacy claims for dronedarone (C180 days' total supply) between June 2009 and March 2011, and with an AF/AFL diagnosis and no heart failure-related hospitalization during the 12 months preceding the initial (index) dronedarone claim. Annualized inpatient and outpatient resource utilization were compared between the pre-index (baseline) and post-index (follow-up) periods. Results: In total, 5,656 AF/AFL patients were prescribed dronedarone for C6 months and were followed for mean (standard deviation) 11.9 (4.7) months. Reductions in mean numbers of annualized all-cause, CV-and AFrelated hospitalizations (*40-45%), and emergency department visits (*30-45%) were realized. These benefits were offset by increases in office visits (*10-30%) and AF-related prescription claims (74%) after dronedarone Electronic supplementary material The online version of this article (doi:10.1007/s12325-014-0108-x) contains supplementary material, which is available to authorized users.
INTRODUCTION
Atrial fibrillation (AF) and atrial flutter (AFL) collectively affect an estimated 3.3 million adults in the USA and confer increased cardiovascular and cerebrovascular risk [1] .
Patients with AF/AFL are more likely than agematched individuals without AF/AFL to have other cardiovascular and cardio-metabolic conditions [1] [2] [3] . Moreover, the presence of AF/AFL worsens the prognosis of patients with cardiovascular comorbidities, elevates the risk of stroke and doubles the risk of mortality [4, 5] .
AF is considerably more frequent than AFL, and accounts for [90% of all cases of AF/AFL [1] . In the USA, AF-associated hospitalizations and deaths have been increasing steadily over the past 30 years [6] , and one in three patients can expect a cardiovascular-related hospitalization within the first year following diagnosis of AF [6] .
Clinical trials have provided evidence of significant improvements in patient-centered outcomes in AF, including decreased rates of stroke, cardiovascular hospitalization, and cardiovascular mortality [7] [8] [9] . Whether trial-tested outcomes translate into improved outcomes in the real-world setting is not well studied and remains an important clinical question. Although randomized clinical trials are important in establishing treatment efficacy, their emphasis on internal validity often limits the generalizability of their findings [10] .
Differences in patient selection, treatment conditions, and practice patterns between the clinical trial and the real-world setting can influence treatment outcomes [11] . Important patient subgroups, including the elderly, and those with coexisting morbidities, are frequently under-represented in clinical trials of cardiovascular drugs [12, 13] . Likewise, AF clinical trial populations vary in their representativeness to real-world AF patients [14, 15] 
METHODS

Data Source
This study used administrative claims data from the score [20] , and AF-related medication (rhythmcontrol, rate-control, and anticoagulation) use were determined over the baseline period.
Healthcare resource utilization, comprising inpatient services (hospital facility and professional), outpatient medical services (emergency department and office visits, 
RESULTS
Patient Characteristics
In total, 5,656 AF/AFL patients met the study eligibility criteria (full study population) and were prescribed dronedarone for C6 months.
The full study population was predominantly male (62%), had a mean age of 68.3 years, and included patients enrolled in managed care systems as well as fee-for-service health plans ( (Fig. 3 ). Initiation of dronedarone treatment was also associated with increases in the mean number of Table 2) .
Prior Rhythm-Control Cohort
Similar changes in pattern of healthcare resource utilization to those described in the full study population occurred in the Prior Rhythm-Control cohort after initiation of dronedarone ( Figs. 1, 2) . Marked reductions in the mean numbers of all-cause hospitalizations (-33%) and emergency department visits (-36%) and in the total length of hospital stay (-34%) were accompanied by an increase in the mean number of all-cause prescription claims (?13%) (all P\0.0001) after introduction of dronedarone ( Figs. 1, 2) . Cardiovascular-and AF-related hospitalizations (-35% and -39%), emergency department visits (-49% and -53%), and AF-related prescription claims (?26%), as well as durations of cardiovascularand AF-related hospital stay (-36% and -37%) (all P\0.0001) were affected in a similar manner (Figs. 1, 2) .
Comparison of treatment patterns between
the baseline and follow-up periods revealed similar levels of coverage with rate-control therapy (80.3% vs. 77.5%) and anticoagulant therapy (67.1% vs. 69.1%), but reduced use of other rhythm-control agents (18.0%) after introduction of dronedarone. Despite sharp reductions (C90%) in numbers of claims for amiodarone and sotalol, the overall mean number of antiarrhythmic drug claims during the follow-up period was 55% higher than during the baseline period, with dronedarone accounting for most of these ( Table 2 ).
Initiation of dronedarone treatment was also associated with increases in mean numbers of prescription claims for anticoagulant drugs (?22%, P\0.0001), including warfarin (?10%, P\0.001) and dabigatran (?2,000%, P\0.0001) ( Table 2 ).
DISCUSSION
The present analysis reinforces the findings of the ATHENA trial by indicating that the reductions in cardiovascular hospitalization obtained with dronedarone in the controlled clinical trial setting extend to the broader population of AF/AFL patients-both those initiating rhythm-control therapy and those [22] , led to the revised recommendation that dronedarone should be initiated only in patients with nonpermanent AF (but not AFL) who are in sinus rhythm, and discontinued on progression to permanent AF [23] . The therapeutic value of dronedarone, including its risks and benefits, has been reviewed extensively in several articles [24] [25] [26] , with the general consensus that patients being considered for dronedarone therapy be carefully selected and monitored to prevent potential adverse events and drug interactions. As such, current 2011 American In clinical practice, AF/AFL patients at high thromboembolic risk, who represent prime candidates for dronedarone treatment, experience high rates of hospitalization, with approximately 40% requiring readmission within the first 12 months after their initial hospitalization for AF/AFL, resulting in a mean cost per AF hospitalization of US$7,476-8,493 [16, 28] . In keeping with the high volume and temporal pattern of cardiovascular admissions displayed by this high-risk patient population, the study findings suggest that the benefit of reduced hospital resource utilization associated with dronedarone is realized promptly, within 12 months of commencing treatment.
With the healthcare costs of AF/AFL currently estimated at $26 billion annually [29] , and the number of cases of AF/AFL in the US predicted to rise to more than 8 million over the next 30-40 years [1] , the development of treatments that can reduce the need for cardiovascular admission assumes importance in restraining the growing cost burden of this condition. The recent ACC and Institute for Healthcare Improvement-led Hospital to Home initiative was designed to reduce 30-day all-cause readmission rates for patients discharged with heart failure or acute myocardial infarction by 20% nationwide [30] . It is feasible that a national quality initiative of this type might also be applied to the management of AF/AFL, with the aim of reducing hospital admissions and improving the transition of care from the inpatient to outpatient setting; one element of this would be improvement of post-discharge medication management. Similarly, the increase in anticoagulation use following dronedarone initiation (coverage rose to *69% of patients in both groups) may have been a consequence of the increased number of office visits (i.e., improved patient care) and closer adherence to treatment guidelines. Thus, it cannot be excluded that some of the benefits associated with dronedarone may be due to improved anticoagulation and/or overall patient care. Finally, patients selected for inclusion in this study were required to have demonstrated reasonable persistence (C6 months) with dronedarone therapy, in keeping with the ATHENA trial population, whereas in clinical practice initial rhythm-control therapy is often associated with high rates of discontinuation [31] .
CONCLUSIONS
This study extends the findings of the ATHENA trial by indicating that either first-or secondline treatment with dronedarone substantially reduces the rate of cardiovascular hospitalization among AF/AFL patients in realworld practice. The reduction in number and duration of hospitalizations that follows initiation of dronedarone treatment is offset in part by a modest increase in office visits and a more marked increase in AF-related prescriptions claims (mainly on account of claims for dronedarone itself).
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